Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>

Spremljeno u:
Bibliografski detalji
Glavni autor: Qingsheng Xu (17078830) (author)
Daljnji autori: Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Izdano: 2025
Teme:
Cancer
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
CNS Cancers
Gliomas, Glioblastomas
Precision Medicine
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Opis
Sažetak:<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>

Slični predmeti